Claims
- 1. A method for treating an eosinophil-associated pathology comprising co-administering to a mammal in need of such treatment an amount of a topical anesthetic and an amount of a glucocorticoid, wherein said amounts are effective to counteract at least one of the symptoms of said pathology.
- 2. The method of claim 1 wherein the mammal is a human.
- 3. The method of claim 1 wherein the pathology is bronchial asthma, eosinophil-associated intranasal inflammation, inflammation of the paranasal sinuses, allergic rhinitis, eosinophil-associated cutaneous inflammation, eosinophil-associated disorders of the gastrointestinal tract or eosinophil-associated inflammation of the eye.
- 4. The method of claim 3 wherein the pathology is bronchial asthma.
- 5. The method of claim 1 wherein the topical anesthetic and the glucocorticoid are administered to the respiratory tract of said human, by spraying or by nebulization.
- 6. The method of claim 5 wherein the topical anesthetic is administered in combination with a pharmaceutically acceptable liquid vehicle.
- 7. The method of claim 1 wherein the topical anesthetic is administered at a daily dose of about 0.05-15 mg/kg.
- 8. The method of claim 1 wherein the topical anesthetic is an N-arylamide aminoalkylbenzoate or a pharmaceutically acceptable salt thereof.
- 9. The method of claim 1 wherein the topical anesthetic is an aminoalkylbenzoate or a pharmaceutically acceptable salt thereof.
- 10. The method of claim 8 wherein the topical anesthetic is an N--(C.sub.7 -C.sub.22) arylamide of an amino-substituted (C.sub.1 -C.sub.5) - carboxylic acid or a pharmaceutically acceptable salt thereof.
- 11. The method of claim 10 wherein the topical anesthetic is an N-�(mono- or di-(C.sub.1 -C.sub.4) alkyl) phenyl!amide of an aliphatic (C.sub.1 -C.sub.5) carboxylic acid, wherein said acid is substituted with (R)(R.sup.1)N--, wherein R is H or (C.sub.1 -C.sub.5)alkyl and R.sup.1 is (C.sub.1 -C.sub.5) alkyl; or a pharmaceutically acceptable salt thereof.
- 12. The method of claim 11 wherein the topical anesthetic is lidocaine, prilocaine, or etidocaine or a pharmaceutically acceptable salt thereof.
- 13. The method of claim 12 wherein the topical anesthetic is lidocaine or lidocaine hydrochloride.
- 14. The method of claim 9 wherein the topical anesthetic is an ester between a carboxylic acid of the general formula:
- (R.sup.2)(R.sup.3)ArCO.sub.2 H,
- wherein Ar is C.sub.6 H.sub.3 and each R.sup.2 and R.sup.3 is H, halo, (R.sup.5)(H)N--, H.sub.2 N--, or (C.sub.1 -C.sub.5)alkyl, and an alcohol of the general formula:
- (R.sup.4)(R.sup.5)N(X)OH
- wherein X is a branched- or straight-chain (C.sub.1 -C.sub.5)alkylene; R.sup.4 is H or (C.sub.1 -C.sub.4) alkyl, R.sup.5 is (C.sub.1 -C.sub.4)alkyl or R.sup.4 and R.sup.5 taken together with N are a 5- or 6-membered heterocycloaliphatic ring, optionally substituted by (C.sub.1 -C.sub.3) alkyl or comprising an additional ring O-- or N-- atom, or a pharmaceutically acceptable salt thereof.
- 15. The method of claim 14 wherein the topical anesthetic is procaine, chloroprocaine, dyclonine, tetracaine, benoxinate, proparacaine, meprylcaine, piperocaine or a pharmaceutically acceptable salt thereof.
- 16. The method of claim 1 wherein the topical anesthetic is bupivacaine, dibucaine or a pharmaceutically acceptable salt thereof.
- 17. The method of claim 1 wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisol, cortisone, dexamethasone, flumethasone, fluocinolone, fluocinonide, fluorometholone, flurandrenolide, fluticasone, meprednisone, methylprednisolone, prednisolone, triamcinolone, amcinonide, desonide, desoximetasone, or a pharmaceutically acceptable salt thereof.
- 18. The method of claim 17 wherein the glucocorticoid is betamethasone, cortisol, cortisone, dexamethasone, meprednisone, methylprednisolone, or prednisolone, or a pharmaceutically acceptable salt thereof.
- 19. The method of claim 18 wherein the glucocorticoid is dexamethasone, or a pharmaceutically acceptable salt thereof.
- 20. The method of claim 1 wherein said amounts are co-administered simultaneously.
- 21. The method of claim 20 wherein a pharmaceutical composition is administered comprising the amount of said topical anesthetic and the amount of said glucocorticoid.
- 22. The method of claim 20 wherein a first pharmaceutical composition comprising said topical anesthetic in combination with a pharmaceutically acceptable carrier is administered simultaneously with a second pharmaceutical composition comprising said glucocorticoid in combination with a pharmaceutically acceptable carrier.
- 23. The method of claim 1 wherein said amounts are administered sequentially.
GOVERNMENTAL RIGHTS
This invention was made with the assistance of the United States Public Health Service under grant number AI-15231. The U.S. Government has certain rights in the invention.
US Referenced Citations (6)
Foreign Referenced Citations (1)
Number |
Date |
Country |
9417790 |
Aug 1994 |
WOX |